Iradimed Corp. (IRMD), Friday revealed that the company expects fourth quarter preliminary unaudited revenue growth of 10 to 11 percent, to the range of approximately $19.2 million to $19.4 million.
For the full year, the company projects revenue of approximately $73.1 million to $73.3 million, compared to $65.6 million in the prior year for the full year 2024.
Currently, Iradimed's stock is trading at $57.25, down 1.65 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.